Navigation Links
Pharmatek Laboratories Expands GMP Manufacturing Capabilities
Date:10/4/2010

SAN DIEGO, Oct. 4 /PRNewswire/ -- Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has added roller compaction to its solid oral dosage form manufacturing capabilities.  The company has purchased two roller compactors, a pilot-scale Vector TFC-220 roller compactor with a rate of 20 kg/hour, and a Vector TFC-LAB Micro lab-scale roller compactor with a rate of 1 kg/hour.  Both machines have been integrated into Pharmatek's GMP facility and are ready for GMP manufacturing.

"The addition of roller compaction expands our granulation capability, especially in the area of moisture sensitive and density-challenged API's.  When used in conjunction with our microdose capsule filling technology (Xcelodose 600S and Symyx Powdernium MTM2005), roller compaction also provides an option for larger fill weights in powder-in-capsule dosage forms," said Kevin Rosenthal, Director of Manufacturing.  "Additionally, with the purchase of two roller compactors we now have dry granulation capability in our highly-potent and non-highly-potent manufacturing facilities."

Pharmatek has also complemented existing manufacturing capacities by expanding single-batch blending size capabilities three-fold (up to 36kg) with the acquisition of a 3 cu. ft. V-blender, and increasing capsule and tablet production by purchasing a Bosch GKF400 automated encapsulator with a rate of 23,000 capsules/hour and a Korsch PH-106 instrumented tablet press with rate of 32,400 tablets/hour.

"With the roller compactors, Pharmatek can now support a broad range of solid oral formulations that previously were not optimal or feasible using our existing wet granulation equipment due to moisture sensitivity.  The 3 cu. ft. V-blender and Bosch encapsulator have positioned us well for large-scale Phase II clinical trial manufacturing," stated Jeff Bibbs, CEO and CSO of Pharmatek.  "Also, by expanding our existing encapsulation and tablet manufacturing capabilities, we can better serve our clients' clinical drug supply needs as they move beyond small-scale development and transition to GMP manufacture of drug product for clinical trials."

For a complete listing of Pharmatek's manufacturing equipment and capabilities, please visit www.pharmatek.com/gmp-manufacturing.html.

About Pharmatek Laboratories, Inc.Pharmatek Laboratories Inc. is a premier pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry.  Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, and cytotoxic and high-potency development.

Statements contained in this media release which are not historical facts may constitute forward-looking statements.  All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected including sales forecasts and strategic expansion.  The trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry, Pharmatek Formulation Screening, Pharmatek University and PTEK U are all property of Pharmatek Laboratories, Inc.  Additional information about Pharmatek Laboratories may be obtained at the Web site http://www.pharmatek.com or by calling 858-805-6383.Company Contact:Ryan Lane, Marketing CoordinatorPharmatek Laboratories, Inc.(858) 805-6383 x284rlane@pharmatek.comAvailable Topic Expert(s): For information on the listed expert(s), click appropriate link.

Jeffrey A. Bibbs

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=48157

Timothy M. Scott

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=50335


'/>"/>

SOURCE Pharmatek Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmateks Highly-Potent and Cytotoxic (HP/C) Facility Positions It as Industry Leader in Development and Manufacturing of HP/C Compounds
2. Pharmatek Laboratories Announces Acquisition of the First Xcelodose(R) 600S System on the West Coast
3. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
4. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
5. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
6. Romark Laboratories Raises $18 Million in Institutional Financing
7. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
8. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
9. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
10. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
11. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... May 5, 2016 ... addition of the  "Europe Thrombocythemia Market ...  report to their offering.  ... , ,The latest research Europe Thrombocythemia ... 2016, provides comprehensive insights into Thrombocythemia ...
(Date:5/5/2016)... , May 5, 2016 ... of the  "Europe Thalassaemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Thalassaemia Market and Competitive Landscape Highlights - ... products, Thalassaemia epidemiology, Thalassaemia market valuations and ...
(Date:5/4/2016)... Westport, Conn., May 4, 2016  Compass Diversified Holdings ... the "Company"), an owner of leading middle market businesses, ... months ended March 31, 2016. First Quarter ... Distribution and Reinvestment ("CAD" or "Cash Flow") of $13.6 ... Reported net loss of $15.0 million for the first ...
Breaking Medicine Technology:
(Date:5/5/2016)... IN (PRWEB) , ... May 05, 2016 , ... ... benefits advisory organization, announces McLaughlin & Smoak Benefits as the latest addition to ... Smoak Benefits has a dedicated team of compliance, wellness, human resources, and health ...
(Date:5/5/2016)... ... May 05, 2016 , ... Michael ... charity program created to assist the people of their local community. The agency ... organizations and community leaders. Their hope is to bring awareness to important local ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... community enrichment program serving families of greater Dubuque, IA. The current campaign fundraises ... and honorably discharged veterans. Donations to Veteran’s Freedom Center may now be made ...
(Date:5/5/2016)... ... May 05, 2016 , ... TIME for Kids and The ZAC Foundation – ... partnership to reach nearly 1 million children with important water safety messages before summer ... leading cause of accidental death in children one to 6 years of age. ...
(Date:5/5/2016)... ... 05, 2016 , ... The 2016 Nike Soccer Camp will be directed by ... coaching staff. Together they bring their winning Vandals coaching philosophy to young athletes. Programs ... 5-13, and high school players. Session dates are as follows: , Youth Day Camp ...
Breaking Medicine News(10 mins):